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ABSTRACT
Fluid dynamics have long influenced cells in suspension. Red blood cells and white blood cells are advected through biological microchannels
in both the cardiovascular and lymphatic systems and, as a result, are subject to a wide variety of complex fluidic forces as they pass through.
In vivo, microfluidic forces influence different biological processes such as the spreading of infection, cancer metastasis, and cell viability, high-
lighting the importance of fluid dynamics in the blood and lymphatic vessels. This suggests that in vitro devices carrying cell suspensions may
influence the viability and functionality of cells. Lab-on-a-chip, flow cytometry, and cell therapies involve cell suspensions flowing through
microchannels of approximately 100–800 μm. This review begins by examining the current fundamental theories and techniques behind the
fluidic forces and inertial focusing acting on cells in suspension, before exploring studies that have investigated how these fluidic forces affect
the reactions of suspended cells. In light of these studies’ findings, both in vivo and in vitro fluidic cell microenvironments shall also be
discussed before concluding with recommendations for the field.
© 2020 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/5.0005154
I. INTRODUCTION
The transport of cells by fluids at the sub-millimeter scale
plays a key role in physiology and bioprocessing.
Red blood cells (RBCs), white blood cells (WBCs), and some-
times cancer cells are advected through biological microchannels in
both the body’s cardiovascular system (CS) and the lymphatic system
(LS) and, as a result, are subject to a wide variety of complex fluidic
forces as they pass through. Here, these microfluidic forces influence
different biological processes such as the spreading of infection,
cancer metastasis,1 and cell viability,2–9 highlighting the importance
of fluid dynamics in the blood and lymphatic vessels.
These forces are not only determined by the channel and
fluid properties, but also by the mechanical properties of the cells
themselves. The deformability of suspended cells can change due
to illness or disease progression,10–19 inciting a change in the
deformability-induced lift experienced by these cells, which in
turn causes a change in the distribution of cells across the
channel width20,21 which can be exploited in cell separation
techniques.13,22,23
It is, therefore, likely that the forces experienced by cells
flowing in devices may affect both viability and functionality.24
Lab-on-a-chip and other microfluidic devices and techniques, such
as flow cytometry and cell sorting, involve cell suspensions flowing
through microchannels. These techniques are already commonly
used in widespread applications ranging from clinical settings to
research environments.
At present, the effects that fluid mechanics exert on cells in sus-
pension have largely remained unexamined.24,25 Despite the fact that
it is desirable for cells to retain their integrity following such diagnos-
tic procedures, it is not considered to be essential. However, the topic
is rapidly gathering importance with the recent emergence of cell
therapies. Methods such as chimeric antigen receptor (CAR) T-cell
therapy or adoptive T-cell transfer therapy, require the removal of
cells from the patient, cell processing and reintroduction of the cells
to the individual, carried out via microchannels. With the extraction
of cells from the bodies of immunologically compromised patients,
there exists a critical need to ensure that the viability or functionality
of the precious supply of cells has not been compromised.
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These findings will be important considerations in the design
of such devices for both diagnostic and research purposes, but is of
particular concern in cell therapy whereby cells are returned to the
body following treatment. Therefore, it is important to understand
completely the forces that suspended cells are subject to, both
in vivo and in vitro, as they may affect the viability and functional-
ity of the cells.
This review begins by examining the current fundamental the-
ories behind the fluidic forces and inertial focusing acting on parti-
cles, and by extension, cells, in suspension, before exploring studies
which have investigated how these fluidic forces affect the reactions
of suspended cells. An examination of both the in vivo and in vitro
cell environments shall be discussed in light of these studies’ find-
ings and how the results can be interpreted in such contexts before
finally, concluding with recommendations for the field.
II. THE THEORETICAL MECHANICS OF PARTICLE FLOW
The behavior of fluids and their suspended particles change as
the scale of the channel changes from the macroscale to the micro-
scale. Often the behavior of cells, being of somewhat similar size
and shape, can be related to suspended particles. Here, the theory
behind the behavior of these particles and cells is described as well
as the fluids they are suspended in.
A. Poiseuille flow
The physics of flow in a pipe provide the fundamental theories
behind fluid flow in the channels of the body as well as in in vitro
microfluidic channels. Poiseuille flow, the fully developed, laminar,
pressure-driven flow of an incompressible fluid in a circular pipe,
can be described using the equation




where U(r) is the fluid velocity profile with respect to the channel
radial position, r, U is the mean velocity, and R is the channel
radius, resulting in a maximum fluid velocity at the channel’s
center. The shear stress [τ(r)] across the channel width can be
defined as






where τ(r) is the shear stress profile with respect to the channel
radial position. This results in the largest τ(r) in the channel at the





where D is the diameter of the channel. Note that both τ(r) and τw
are the shear stress values that a particle experiences at a point in
the channel due to its radial position, and is not necessarily the
shear stress gradient acting on the surface of the particle (∇τp).
The Reynolds number (Re), used to describe the relationship





where ρ is the density of the fluid. Pipe flows with a Re . 2000 can
be described as turbulent flow, while below this figure, the flow is
usually laminar. In microchannel flow, due to the small channels
and flow rates, the viscous forces dominate and Re is quite low as a
result. For this reason, microfluidic flow is usually laminar.26
B. Particle flow
The first studies examining the inertial migration of particles
was carried out by Segré and Silberberg in 1962.27,28 They found
that in a circular pipe, particles formed an annulus at a distance of
0.6 of the channel radius from the channel center. This effect was
subsequently named the Segré–Silberberg effect. Interestingly, this
effect does not only take place at the macro-level, but also at the
micro-level. Subsequent studies have shown that a number of
channel properties influence the inertial migration of these parti-
cles. The forces that these particles are subject to have also been
examined.
1. Channel properties
A number of channel and flow properties influence the inertial
migration of particles in a straight, regular channel, including the
Reynolds number, particle Reynolds number, the channel focusing
lengths, and the channel geometry.
1. Reynolds number. The Reynolds number [as described in
Eq. (4)] influences the positions of particles. At low Re, particles
focus toward the Segré–Silberberg positions, while at very high Re,
they focus at the channel center.29,30 Interestingly, despite the
strong influence that Re has on the inertial positions of rigid parti-
cles, computational studies have shown that Re has little to no
impact on the migration of deformable particles, or cells, in circular
channels.31
2. Particle Reynolds number. The particle Reynolds number
(Rep) is one of the main descriptors of particle behavior in a fluid
flow. Rep in a circular pipe is defined as
Rep ¼ Re dpD
 2
, (5)
where dp is the diameter of the particle. The Rep can be used to
describe the point at which the inertial migration of particles
begins to take place. Previous experimental studies have shown that
Rep needs to have reached a value of at least 0.05 with a particle to
diameter ratio (dpD) of at least 0.07 in order for particle migration to
have occurred.32
3. Channel length. An appropriate channel length is required
in order for particles or cells to reach equilibrium Positions;
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however, there is no consensus among microfluidic experts on a
single equation and several formulas have been proposed in order






where LM is the migration length. This equation was also used by






where Umax is the maximum velocity of the fluid (normally at the
channel center) and CL 0.04 with a channel aspect ratio of 1 (CL
varies from approximately 0:02–0:05 as the channel aspect ratio
(HW, where H is the channel height and W is the channel width)
varies from 2 to 0.5). This expression was favored by Amini et al.35
and Martel and Toner.36
4. Channel geometry. The geometry of the channel signifi-
cantly affects the equilibrium positions of particles and cells alike.
As previously described, in circular channels, particles form an
annulus at 0.6 of the channel radius. In square channels, particles
equilibrate at the center of the channel walls as seen in Fig. 1. An
increase in the flow rate results in particles moving closer to the
walls. In rectangular channels, the particles equilibrate at the center
of the two larger walls. This can also be seen in Fig. 1. In this
instance, as the flow rate is increased, particles at the longer edge
move toward the walls, similar to square channels, while particles
also start to form equilibrium positions at center of the shorter two
walls.26,32–43 As this study focuses primarily on circular microchan-
nels, the behavior of particles in channels of different geometries is
not explored in great detail here. Further reading on the topic is
available at the above references.
2. Particle forces
Both particles and cells flowing in a microchannel have
normal and shear stresses acting on their surfaces. These can be
FIG. 1. Particle equilibrium positions in different channel geometries in (a) a square channel, (b) a rectangular channel, and (c) a circular channel. As the flow rate
increases, particles migrate to positions in the directions of the arrows.
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divided into lift forces (due to normal stresses) and drag forces
(due to shear stresses). Lift forces include the wall-induced lift,
shear-gradient-induced lift, Saffman (or slip-shear-induced) lift,
Magnus (or rotation-induced) lift, and deformability-induced lift,
while drag forces include viscous drag. The lift forces are illustrated
in Fig. 2.
1. Inertial lift force. The main force acting on a particle is the
inertial lift force (FI), which also plays a significant part in cellular
focusing. This is a balance between the wall-induced lift (FI(W)),
and the shear-gradient-induced lift [FI(SG)], as shown in Fig. 2.
When a particle flows close to the channel wall, fluid streamlines
around the particle are directed to its opposite side. This creates a
pressure difference between the two sides of the particle, causing it
to be directed toward the channel center by FI(W). This can be
expressed as FI(W) / ρ(Umax)
2dp
6
D4 . Conversely, FI(SG) opposes FI(W). As
previously discussed, in Poiseuille flow, the velocity profile is para-
bolic. Due to this, the fluid velocity relative to the particle velocity
will be larger on the wall side of the particle than on the side closer




directs the particle toward the channel wall.26,32–36,38–49 FI was







where fL is the lift coefficient. This was completed by matching
the inner and outer flow region pressures and velocities. This
equation holds true as long as the particle size is much smaller
than the size of the channel (dpD  1). As FI / dp4, larger cells have
much larger FI acting on them, which could have potential implica-
tions for cell viability.
2. Saffman lift force. As a particle flows in a microchannel,
drag forces from the wall act on it, causing it to travel at a lower
velocity than the fluid it is suspended in. In this case, a force due to
the slip-shear, the Saffman lift force (FS), causes the particle to
migrate toward the side of the maximum relative velocity. This is
illustrated in Fig. 2. In other words, if a particle is lagging the flow,
FS will direct the particle toward the channel center; however, a
particle leading the flow will be directed toward the wall. It is
worth remembering that in general, FS in a channel will be an
order of magnitude smaller than FI and so can be considered
negligible.33–36,42,48,50–52 FS was also derived using the matched
asymptotic expansion method by Saffman,50






where K is a constant (approximately 81:2), V is the relative veloc-
ity between the fluid and the particle, γ is the velocity gradient, and
ν is the kinematic viscosity. This was completed by matching the
inner and outer velocity expansions. In the context of microchan-
nels, cells tend to lag the flow;20 therefore, though the effect from
FS will be small, it will direct cells toward the channel center.
3. Magnus lift force. A particle in microchannel flow will also
experience a degree of rotation. Due to the difference in the fluid
velocity on either side of the particle, it will rotate in the flow as
seen in Fig. 2. Rotation in the counterclockwise direction, as indi-
cated in the schematic, results in a pressure difference on either
side of the particle with the lower pressure on the side of the larger
fluid velocity (in this case it is the upper side). This causes a force
due to the rotation, the Magnus force (FM), to act in the direction
of lower pressure. In the case of microchannel flow, this is generally
toward the channel center. FM is also very small (usually an order
of magnitude less than FS) in comparison to other lift forces, and
so can be deemed negligible; however, its effects increase signifi-
cantly the closer the particle is to the wall. FM also scales with the
cube of dp.
33,34,41,42,51–54 FM was derived using the matched asymp-
totic expansion method by Rubinow and Keller,53
FM ¼ 18 πdp
3ρ(~V  ~Ω), (10)
where ~V is the relative velocity vector between the particle and the
fluid and ~Ω is the angular velocity vector of the particle. This was
carried out by matching the Stokes and Oseen expansions.
4. Deformability lift force. Deformability-induced lift (FD)
affects non-rigid particles such as cells or vesicles. It has been
argued that FD is due to the shape change that deformable particles
in a flow experience due to fluidic forces;55 however, it can also be
attributed to the surface tension gradients at the interface between
the fluid and particle surface.56 For this reason, the Weber number
FIG. 2. Illustration of the lift forces
acting on a particle in microchannel
flow.
Biomicrofluidics REVIEW scitation.org/journal/bmf
Biomicrofluidics 14, 031501 (2020); doi: 10.1063/5.0005154 14, 031501-4
© Author(s) 2020
[ratio of inertial stress to surface tension, Eq. (11)] and the capillary
number [ratio of viscous stress to surface tension, Eq. (12)], which
both describe the surface tension gradient, along with the viscosity
ratio (between the particle and fluid viscosities, Eq. (13)), which
describes the particle shape, are important. As these numbers can
be used to characterize cell or droplet deformation, which increases
with FD, they can be utilized to estimate its scale.
23 The Weber
















where μp is the viscosity of the particle’s internal fluid. Under
Poiseuille flow, it has been found that a more deformable particle
(or one with a low elastic modulus (E)) migrates toward the
channel center, while stiffer, more rigid particles remain closer to
the channel walls.23,34,35,43,55–58 This can be seen in Fig. 2. The
deformability-induced lift was derived by Chan and Leal57 to be




f (λ p), (14)
where r is the radial position of the particle in the channel, and
f (λp) is defined as





2  λp þ 8)þ 3(19λp þ 16)14(3λp þ 2) (2λp
2  λp  1)
 
, (15)
given that the particle is not too close to the channel walls
(R r . dp) and that 1 , λp , 10.35,57 Based on their experi-
ments, Stan et al.58 then derived an equation for the empirical iner-
tial lift force (FI(D)) on deformable particles





where CL is the lift coefficient, which needs to be experimentally
determined for a given combination of continuous and dispersed
phases.34,35,58 The deformability of the particle also heavily influ-
ences its migration speed, with more deformable particles reaching
equilibrium positions quicker.31
In some instances, when the deformability-induced lift is
larger than those generated by cell or droplet deformation, the
excess lift may be due to Marangoni-like effects.58 The redistribu-
tion of surfactants on the surface of the cell induced by thermal
gradients or uneven shear rates can cause a flow at the interface
between the cell and suspending liquid in the direction of higher
surface tension. As the Marangoni effects affect the distribution of
σ on the cell surface rather than the absolute value of σ, it does not
impact on Ca. However, like Ca, their magnitude depends on the
presence and amount of surfactant.58
1. Cell deformability
Different cell types within the body vary widely in their
mechanical properties, including in their deformability. This is also
true for cells, which are ordinarily suspended in confined flow, pri-
marily RBCs, WBCs, and circulating tumor cells (CTCs). RBCs
have a bi-concave disk shape and are very small in comparison to
other circulating cells, typically sized approximately
5–9 μm,13,22,59–69 and make up approximately 41% of the total
blood volume. They are highly deformable in order to squeeze
through the narrowest capillaries and previous studies that have
examined the deformability of RBCs are outlined in Table I.
The size and shape of WBCs differ between types; however,
the majority are in the region of 8–20 μm in diameter.64,66,70,71
WBCs make up less than 4% of the total blood volume and are also
present in lymph, as opposed to RBCs, which are only found in
blood. In general, WBCs have been found to be less deformable
than RBCs; however, the ability of WBCs to deform has been
TABLE II. Deformability studies of white blood cells.
WBC stiffness Donor Measurement technique Study
2–3 kPa Human Atomic force microscopy 73
85 ± 5 Pa Human Parallel plates 74
1.24 ± 0.09 kPa Human Atomic force microscopy 75
11.2 ± 5.9 kPa Mouse Atomic force microscopy 76




Approximately 650 μPa Human Micropippette
aspiration
10
320 ± 50 μPa Human Laminar flow system 11
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found to be connected to stronger adhesions with vessel endothelial
cells.72 Previous studies investigating these deformabilities are out-
lined in Table II.
CTCs primarily invade through the circulatory systems (blood
or lymph), and it is believed that in the case of solid cancers, up to
80% of tumor dissemination takes place through the lymphatics
while only 20% occurs through the vascular system.77,78 CTCs tend
to be larger than normal cells, measuring approximately
15–25 μm,4,7,20,63,79–84 and this characteristic can be exploited in
some cell separation techniques (see Sec. V B). Circulating cells are
very rare in the blood of cancer patients, occurring at a rate of 1–
100 CTCs per 1 109 blood cells,8,20,63,80,85,86 while their numbers
in lymph have not yet been investigated.20 The stiffness of CTCs
vary depending on the source tissue and the metastatic capabilities
of the cells themselves. Previous studies examining the deformabil-
ities of two different breast cancer cell lines (MCF-7 and
MDA-MB-231 cell lines) are outlined in Table III.
As can be seen here, the discrepancies between different
studies can be quite varied. Different measurement techniques, as
well as different cell media and substrate, can influence the
mechanical properties of the cell.19,90 It has also been found that a
lower E, or softer cell, means the cancer cell no longer firmly fits in
its position in the matrix while it is surrounded by stiffer endothe-
lial cells, allowing the cell to detach and migrate more easily.89
Despite these discrepancies, however, all studies agree with each
other; the more metastatic a cell is, the lower its E and the more
compliable it is.84,92–96
5. Viscous drag force. When a particle flows through a fluid or
a fluid flows past a particle, shear stresses are introduced, resulting





where fdrag is the drag coefficient.
34,42 The drag coefficient has dif-
ferent definitions depending on the Rep. For 104 , Rep , 0:2,
fdrag ¼ 12μVdp : (18)
This results in a FV of
FV ¼ 3πμdpV (19)
or Stokes drag.34 The Dean drag force is imposed on a particle due
to Dean flow, also known as secondary flow, acting perpendicular
to the direction of the main flow. The Stokes drag force scales line-
arly with particle size and secondary flow velocity and inversely
with the channel’s radius of curvature. Therefore, in straight
channels, the Dean drag force can be considered to be
negligible.26,33,35,36,41–43,47 For 0:2 , Rep , 500–1000,
fdrag ¼ 12μVdp (1þ 0:15Rep
0:687), (20)
resulting in a FV of
FV ¼ 3πμdpV(1þ 0:15Rep0:687) (21)
(Refs. 34 and 97). Finally, for 500–1000 , Rep , 2 105,
fdrag ¼ 0:22ρV2 (22)
resulting in a FV of
FV ¼ 0:055πdp2ρV2 (23)
(Ref. 34). In this way, the FV is influenced both in the flow direc-
tion by the mainstream flow and in the lateral direction by the sec-
ondary flow.34
All of the particle forces are summarized in Table IV
III. THE IMPACT OF THE MICROFLUIDIC ENVIRONMENT
ON SUSPENDED CELLS
As shown in Sec. II B, the fluid mechanics in the microchannel
environment have a significant impact on the forces that solid sus-
pended particles are subject to, and consequently, their inertial posi-
tions. Therefore, it is not unreasonable to assume that these same
forces will impact suspended cells flowing in a microchannel, be it in
vivo or in vitro. As cells are living organisms, the microfluidics in the
TABLE III. Deformability studies of breast cancer cells.
MCF-7 cell stiffness MDA-MB-231 cell stiffness Measurement technique Study
… 182 ± 34.74 Pa Constricted microchannel 17
3–4.5 kPa 4–6 kPa Atomic force microscopy 18
36 ± 8 Pa 18 ± 10 Pa Optical tweezers 19
87.3 ± 47.8 kPa 55.6 ± 20.1 kPa Atomic force microscopy 16
30.2 ± 15.0 Pa 12.6 ± 6.1 Pa Optical tweezers 16
285.1 ± 127 kPa 277.3 ± 63.1 kPa Atomic force microscopy 87
275.2 ± 157.4 kPa 257.5 ± 98.4 kPa MEMS resonant sensor 87
1.04 ± 0.27 kPa … Atomic force microscopy 88
800 ± 20 Pa 500 ± 25 Pa Atomic force microscopy 89
… 0.40 ± 0.22 kPa Atomic force microscopy 90
300–450 Pa … Atomic force microscopy 91
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TABLE IV. Summary of lift and drag forces acting on a particle in microchannel flow.
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channel can affect more than just their trajectories within the
channel. Fluidic forces have been shown to influence the viability or
functionality of living cells,6 while they may also influence cell
behaviors such as cell adhesion to the vessel wall.86
A. Cell viability
Due to the extremely low efficiency of the process of metastasis
(less than 0.01% of CTCs form a tumor at a secondary
site7–9,85,98–101), many researchers hypothesize that high τ(r) in the
vasculature can cause cell death.99,102–107 Contrastingly, others argue
against this conjecture that CTCs are not mechanically fragile and
have developed certain mechanisms to prevent damage from τ(r) in
the circulatory environment.8,86,108,109 Furthermore, they argue that
certain levels of τ(r) in fact promotes CTC invasion110–113 and can
simulate the growth of cancer cell clusters.114 A number of studies
investigating the proposition have been conducted through different
methods and are outlined below.
1. Cone and plate experiments
A cone and plate viscometer can be used to replicate Couette
flow by applying a uniform, consistent τ(h) to cells which are
adherent to a plate115 (see Fig. 3). This method has been used by
different studies to examine the viability of cancer cells under cons-
tant flow conditions, finding that the viability of B16 melanoma
cells is reduced to 0 after exposure to τ(h) levels of 2.9 Pa for 5.5 h,
while ovarian cancer cells exposed to τ(h) levels of 1.2 Pa had
reduced viability by 30% after 10 min.8 Further studies have found
that exposure of breast cancer cells to 6 Pa for a 24 h period results
in a cell viability of close to 0.21 These studies all conclude that
cells exposed to a threshold τ(h) level over a considerable time
frame will result in cell death. However, while useful for applying a
constant, known τ(h) value, the cone and plate setup does not
mimic the pipe-imposed shear that suspended cells would ordinar-
ily be exposed to in vivo or in vitro.
2. Syringe and needle experiments
The syringe and needle method, consisting simply of a sus-
pended cell solution, injected via a syringe through a needle of
known diameter, is one of the simplest methods for replicating
Poiseuille flow (see Sec. II B). In the implementation of this
method, experiments typically last seconds, rather than hours. For
this reason, very high τw values were examined. It was found in
several studies that τw values of approximately 600–640 Pa resulted
in cancer cell viability of 50%–80% following 10 min of expo-
sure.2,3,109 Others have found that under lower τw values (2–6 Pa),
cancer cell viability was unaffected.116 Additionally, it has been
found that 450–560 Pa applied to RBCs is enough to rupture their
membranes.8 The studies indicated that non-transformed cells were
not able to withstand such high τw values that cancer cells were,
indicating that CTCs possess a property of cellular transformation
that provides them with a certain resistance to τ(r), protecting
them in vivo.
3. Continuous flow circuits
Continuous flow circuits, comprising a peristaltic pump, circu-
lating suspended cells around a flow circuit, have also been used.
While this model more closely represents the pulsatile flow and
resulting τw that cells are exposed to in the CS, it fails to entirely
capture the fluid dynamics of the CS.8 Additionally, peristaltic
pumps may also impose additional forces on cells, causing cell
death to be incorrectly attributed to the wall shear stresses in the
tubing.21 τw values are orders of magnitude lower than those expe-
rienced in the syringe and needle experiments, while viability rates
in these systems are much lower than those observed in the cone
and plate experiments, with periodic, pulsatile exposure to τw of
approximately 6 Pa reducing the viability of suspended cells down
to only 20%, or even less in some cases, over 18–24 h.5–7 In other
cases, τw of 3 Pa over 24 hrs had a similar effect,
4 while a τw of 2 Pa
over 12 h reduced cell viability to below 40%.9 Further studies have
found that τw of 1.6 Pa over 12 h resulted in a viability level of
approximately 40%; however, cells in suspension, but not circula-
tion, over the same period of time resulted in similar viability
levels, suggesting that cell death may be attributed to anoikis rather
than being solely due to the fluidic conditions in the channel.25
Interestingly, the same experimental setup has been used to dem-
onstrate that certain levels of shear stress (approximately 3 Pa),
below that which will cause a decrease in cell viability, acts as a
stimulant for cancer cell migration,117 while shear stress on circu-
lating cells can enhance certain anti-cancer drugs.118
In both the syringe and needle methods and continuous flow
circuits, due to the fact that the cells are in suspension, it is difficult
to determine the actual shear that the cells were subjected to. For
this reason, while utilizing both of these experimental setups, τw
was calculated using Eq. (3) and this was assumed to be the shear
stress that the cells were exposed to in the channel. However, the
cells would only experience these levels of stress if they were travel-
ing at the wall and do not perturb the flow. Therefore, from a via-
bility perspective, it is necessary to know where the cells are located
if the local fluid Poiseuille shear stress is to be estimated.
B. Cell inertial positions
A large number of studies have been carried out on the iner-
tial positions that cells occupy in microchannel flow, replicating
conditions that cells may be exposed to in in vitro microenviron-
ments or lymphatic conditions. Particle focusing does not occur in
turbulent, pulsatile flow, and so these regimes remain unstudied in
this context. Cell behavior differs from particles due to their large
size distribution119 and deformability. The locations of the cells
within the channels are the key to understanding the forces that the
FIG. 3. A cone and plate setup applies a constant shear stress profile to adher-
ent cells.
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cells are subjected to, particularly τ(p), if Poiseuille flow is to be
assumed. Numerous techniques have been employed to investigate
these inertial effects, including particle streak imaging, particle
density measurements and particle tracking. These are explored in
further detail below. For all of the following techniques in micro-
fluidics, fluorescent particles or cells flowing in a microchannel are
illuminated using a laser or an LED, and visualized using an
inverted microscope and attached camera.
1. Particle streak imaging
One of the most common, fundamental techniques for assess-
ing particle migration is particle streak imaging. This can be carried
out simply by focusing a microscope at the channel center and over-
exposing the shutter of the attached camera, creating a streak image.
Brighter areas imply greater particle densities. Examples of streak
images can be seen in Fig. 4. These can be used as standalone
images or the image intensities can be averaged over a number of
similarly obtained graphics. They are one of the most straightforward
methods of assessing the inertial positions of particles.
Particle streak imaging has previously been used in a number
of different studies to assess particle positions in a microchannel.
Di Carlo et al.38 used it in order visualize particle focusing in
curved microchannels, while Bhagat et al.32 and Liu et al.120 also
used streak imaging to determine the different inertial positions of
particles under different Rep in a square and rectangular micro-
channel respectively. Additionally, Bhagat et al.32 visualized particle
separation (which will be explored in further detail in Sec. V B).
Zhou and Papautsky41 were able to use it to calculate the migration
distances and focusing lengths of particles and, therefore, the lift
coefficient on the particles. The effects of viscosity, cross-sectional
channel shape and flow rate were demonstrated by Raoufi et al.121
using streak imaging [see Fig. 4(b)]. Finally, streak imaging has also
been used in biological applications in order to observe DNA
focusing and particle focusing in blood in microchannels.71,122
Particle streak imaging is useful for small particle sizes in relation
to the channel width and is advantageous in that minimal image
post-processing steps are required. Experimental time frames are
also generally very short (in the order of seconds); however, this
could also be construed as a disadvantage.
2. Particle density measurements
Like streak imaging, particle density measurements are an
Eulerian method of evaluating the inertial positions of particles. This
involves taking short exposure images at large intervals. The particle
centers are identified and stacked on one image. An example of this
can be seen in Fig. 5. Following this, the probability density function
(PDF) can be used to evaluate the spatial distribution of the particles









Ni(r, r þ dr)
, (24)
where I is the number of images in the sequence, Ni(r, r þ dr) is the
number of particles between the radial positions r and dr, and R is
the radius of the channel.29,82
Particle density measurements have previously been used in a
number of different studies to assess particle locations. This techni-
que has primarily been used to investigate particle migration under
different Re,29,33,123–131 and different particle shape.132 Park et al.133
used particle density measurements in order to observe particle dis-
tribution in a multi-orifice microfluidic channel, while, again, like
FIG. 4. Examples of particle streak images: (a) 30 μm fluorescent particles flowing in a 300 μm inner diameter (ID) circular microchannel at 9:72 102 μl/min, red lines
represent the channel walls, and the exposure time was set to 10 ms. (b) 10 μm fluorescent particles flowing in a 75 μm square microchannel, white dotted lines represent
the channel walls, and the exposure time was set to 800 ms. Reproduced with permission from Raoufi et al., Biomicrofluidics 13, 13 (2019). Copyright 2019 AIP Publishing
LLC.
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streak imaging, particle density measurements have been used in
biological applications with Tanaka et al.82 investigating the inertial
migration of cancer cells in blood, and Kulasinghe et al.134 investi-
gating the migration of cancer cells and cell clusters in square
microchannels. Particle density measurements are useful for high
density flows, containing small particles in relation to the channel
width. Though not as simplistic as streak imaging, post-processing
is still less computationally complex than particle tracking.
Sampling windows are usually larger (in the order of minutes),
making them more accurate than the streak imaging process.
3. Particle tracking
Particle tracking can be used in conjunction with particle
tracking velocimetry (PTV). This Lagrangian method involves
tracking a particle over the length of the channel. The particle’s
average lateral position, with respect to the channel center, over the
observation window is measured which is then repeated for many







where Dyy is the dispersion coefficient, t is the time duration, Ni is
the number of tracked particles, and Rn,y is the radial displacement
of the particles.135,136 Examples of particle tracking are shown in
Fig. 6.
Particle tracking has previously been utilized in order to
examine the effects of bidisperse solutions on particle focusing,138
as well as to determine the lateral migration of RBCs in 50, 75 and
100 μm ID circular microchannels135,136,139 [see Fig. 6(c)] and
FIG. 5. An example of particle density images: a number of images are stacked producing an intensity image of the particle distribution of 10 μm particles within 800 μm
ID circular channels.
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cancer cells in square microchannels.20 Particle tracking is more
useful in low density flows, with a large particle to channel size
ratio. Image post-processing steps are slightly more complex than
those of particle density measurements; However, there is a range
of freely available software for such purposes. Unlike streak
imaging and particle density measurements, sampling frames are
dependent on the flow rate in the channel.
Experimental studies, which have investigated deformable parti-
cles flowing in microchannels, are outlined in Table V and are pri-
marily carried out in square or rectangular cross sections, while
some have also been completed in circular cross sections. Fewer
studies have examined the migration of deformable particles in pipe
flow, as opposed to rigid particles, and so, data are only available
over a limited range. Furthermore, those experiments conducted at
lower Re mainly focus on RBCs, causing non-Newtonian pipe flow.
While a large range of studies have investigated the inertial effects of
rigid particles under different viscoelastic conditions,128,140–144 fewer
have examined the same reactions of cells. However, it has been
shown that cell suspensions in viscous fluids focus toward the
channel center due to elastic forces at the wall.68
FIG. 6. Examples of particle tracking: (a) particle tracking image still of 30 μm fluorescent particles flowing in an 800 μm ID circular channel at 45.3 μl/min, analyzed using
the ImageJ plugin, TrackMate.137 (b) All the particle tracks in the same image sequence as (a) collated over 500 images and analyzed using a MATLAB® script. (c)
Particle tracking image still of RBCs flowing in a 100 μm ID circular channel, analyzed using ImageJ plugin, MTrackJ. Reproduced with permission from Pinho et al.,
J. Biomech. 49, 2293 (2016). Copyright 2016 Elsevier.
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It has been found that larger cells migrate more quickly to equi-
librium positions than their smaller counterparts82,134 and larger cells
also migrate more in the direction of the channel center.20,71
Furthermore, it has been demonstrated, by both this group and
others, that FD can cause cells with a lower E to migrate toward the
center of the channel, while stiffer cells are more evenly distributed
across the channel width.20,21,23,81,145 It has also recently been found
that deformable cells travel in microchannels at higher velocities than
rigid particles, which may be a result of deformable cells migrating
toward the channel center.146 Many current microfluidic devices
exploit these described inertial effects due to both cell size and
deformability in order to separate mixed cell solutions (see Sec. V B).
4. Computational studies
Investigations on the inertial migration of both solid and
deformable particles are not only confined to experimental setups,
but have also been studied computationally. Many studies have
examined the migration of rigid particles in a wide variety of envi-
ronments, including square and circular channels, Newtonian and
non-Newtonian fluids, as well as different Re.37,45,46,48,54,140,147–150
Of particular interest are those investigating the effects of particle
shape. It has previously been shown that the shape of rigid particles
can influence their migration patterns in a microchannel.144,151
Notably, it has been shown that centerline-focusing particles typi-
cally have fore-aft asymmetry characteristics, similar to “fish” or
“bottle’-like shapes.151
Further computational studies, which have examined the same
reactions in deformable particles, have used this technique to
model the behavior of RBCs152,153 and others. Magnaudet et al.56
found that the deformability-induced lift can be attributed to the
surface tension gradients at the interface between the fluid and par-
ticle surface. Furthermore, it was found that this deformability also
heavily influences its migration speed, with more deformable




(μm) Channel description Re/Q Study
Cells—head and neck cancer
cells
15 50 × 150 μm2 rectangular cross section—20 mm long Q = 100–200 μl/min 134
Cells—yeast cells
(Saccharomyces cerevisiae)
3–5 75 × 75 μm2 square cross section—5 cm long, 60 × 100 μm2
rectangular cross section—5 cm long, 75 μm Dh trapezoidal cross
section—5 cm long, 75 μm complex cross section—5 cm long
Q = 1–250 μl/min 121
Cells—breast cancer cells
(MCF-7, MDA-MB-231)
14, 18 100 × 100 μm2 square cross section—58.5 mm long Re = 0.02–25 20
Cells—red blood cells N/A 100 μm ID circular cross section Re = 0.007 136
Macromolecules—DNA 0.5–1 5 × 5 μm2 square cross section—4 cm long broadening at 45° to
5 × 50 μm2 rectangular cross section
Re = 0.11–0.33 122
Cells—white blood cells,
prostate cancer cells (PC-3)
9, 17.8 93 × 45 μm2 rectangular cross section—3.5 cm long Re≤ 158 71
Cells—breast cancer cells
(MDA-MB-231)
15 220 × 80 μm2 rectangular cross section—0.5–2 cm long
broadening to 220 × 450 μm2 rectangular cross section, 270 × 70
μm2 rectangular cross section—1.5 cm long broadening to 270 ×
400 μm2 rectangular cross section
Q = 64–256 μl/min 82
Cells—red blood cells 7 350 μm ID circular cross section Q = 17.3 μl/min 60
Cells—white blood cells 8–15 10 × 25 μm2 rectangular cross section—5 mm long, 10 × 50 μm2
rectangular cross section—5 mm long, 10 × 75 μm2 rectangular
cross section—5 mm long, 10 × 12 μm2 rectangular cross section
—1 mm long broadening to 10 × 50 μm2 rectangular cross
section—4 mm, 10 × 12 μm2 rectangular cross section—1 mm
long broadening to 10 × 50 μm2 rectangular cross section—1 mm
broadening to 10 × 100 μm2 rectangular cross section—3 mm,
10 × 25 μm2 rectangular cross section—1 mm long broadening to
10 × 50 μm2 rectangular cross section—4 mm, 10 × 25 μm2
rectangular cross section—1 mm long broadening to 10 × 100
μm2 rectangular cross section—4 mm, 10 × 50 μm2 rectangular
cross section—1 mm long broadening to 10 × 100 μm2
rectangular cross section—4 mm
Q = 5–20 μl/h 70
Cells—red blood cells N/A 75 μm ID circular cross section Re = 0.004–0.005 139
Cells—red blood cells N/A 50 μm ID circular cross section, 100 μm ID circular cross section Re = 0.003–0.005 135
Platelets 2.5 5000 × 100 μm2 rectangular cross section—250 mm long Re = 0.21–0.60 154
Biomicrofluidics REVIEW scitation.org/journal/bmf
Biomicrofluidics 14, 031501 (2020); doi: 10.1063/5.0005154 14, 031501-12
© Author(s) 2020
particles reaching equilibrium positions quicker.31 Additionally,
despite the strong influence that Re has on the inertial positions of
rigid particles, computational studies have also shown that Re has
little to no impact on the migration of deformable particles, or
cells, in circular channels.31
C. Cell adhesion
Previous studies examining cell adhesion have demonstrated
that the expression of signaling factors can enhance the process.
In the LS for example, vascular endothelial growth factor C
(VEGF-C), expressed by lymphatic endothelial cells and primar-
ily responsible for lymphangiogenesis, has been associated with
increased CTC metastasis,155–160 while activated chemokine
receptor CCR7, expressed by T and B lymphocytes, causes cells
to migrate toward lymphatic endothelial cells expressing the
ligand CCL21.161,162 In addition, fluidic forces present in the
channel can also affect cellular adhesion to the vessel walls,
playing a part in both WBC and CTC adhesion.
In WBCs, previous investigations found that shear-induced
cell deformation increases the surface area between a WBC and the
endothelial cell layer, increasing its adhesive potential.163
Furthermore, WBCs, which have adhered to the endothelial layer,
experience a sharp increase in ∇τp when they do so.164 It was
shown that while WBCs require a certain level of τw for adhesion
to occur,72,165 beyond a threshold level (approximately 0:1 Pa), high
τw can cause swelling in the cells and decreased cell stiffness,
leading to a potential lack of integrin anchoring.166,167 In addition
to the flow conditions, the channel geometry also significantly
affects cell adhesion with bond formation much more likely in
curved channels than straight.168
Despite the wealth of knowledge available on WBC adhesion
and extravasation through endothelial cell layers, the same behavior
in CTCs is not understood to a similar extent.165 In order for inva-
sion to occur, the cell must stop or be stopped in its journey
through the vessel. Small vessels can halt the progression of CTCs
by physical occlusion if the vessel diameter is smaller than that of
the cell’s diameter (approximately 10 μm).86 This has been
observed by Kienast et al.169 to occur in the brains of mice where
the blood vessels remain at quite small sizes. Having said this,
larger vessel diameter has also been shown to increase CTC inva-
sion.99 Furthermore, it has been found in larger vessels that
PA / f ct, (26)
where PA is the probability of CTC arrest, fc is the frequency of col-
lision between endothelial ligands and membrane-bound receptors,
and t is the residence time.103,168 Collisions with RBCs have also
been found to influence the trajectories of CTCs.170 Besides the size
of the vessel, its shape also has a significant effect. Like WBCs, it
has been found that circulating cells are more likely to adhere to
the blood vessel wall of a curved vessel, rather than a straight one.
This theory was first looked at in thrombi by Liu et al.;171 however,
it was expanded later to include CTCs with further experimental
and computational fluid dynamics (CFD) studies (using the Lattice–
Boltzmann method) proving this theory.168,172 Furthermore, Yan
et al.172 showed that the rate of adhesion is 1.5 times more likely
in curved vessels than in straight ones. Bifurcations also increase
the likelihood of tumor extravasation.108
Vessel fluid mechanics can also play a significant role.
Circulation patterns can influence the direction that CTCs are
carried, and consequently, their final destination.86 It has been
observed that an increase in the fluid flow rate increases the cell
adhesion in a blood vessel. It is believed that this is due to an
increase in bond formation [or an increase in fc in Eq. (26)], as a
high flow rate increases the chances of interaction between the
CTCs and surrounding particles in the blood.167 Contrasting
studies have found a link between decreased flow velocities and
increased cell arrest.173 In later studies, similar to WBCs, it has
been found that τw also has an effect on the adherence of CTCs to
the vessel wall. Both CFD and experimental studies have shown
that once a certain τw threshold has been reached in the vessel,
bond association and disassociation rates may change, causing the
cells to activate certain receptors and, consequently, become more
likely to adhere to the blood vessel walls172,174,175 and to extrava-
sate.117 It was concluded that unless the τw reaches this level, its
effects can be disregarded; however, this specific τw level is rela-
tively low in comparison to the whole system.1 In further studies by
Mina et al.,111 that utilized microfluidic devices to investigate the
effects of τ(r) on breast cancer cells in a 3D culture, it was found
that lower levels of τ(r) (approximately 0:1 Pa) in the fluid, leads to
increased breast cancer cell invasion in the CS. Again, though this
is a relatively low τw to be found in the CS, it is quite high in com-
parison to the levels found in the LS, implying that τw levels in the
lymphatics and veins86 are optimal for cancer metastasis. Further
studies have shown, however, that increases in τw beyond this level
(to approximately 3 Pa), may result in decreased cell adhesion to
the endothelial cell layer.108,176 It must also be considered that
while a small τw of approximately 0.1 Pa increases the adhesive
capabilities of the CTC, it can also decrease its migration capabili-
ties.102 Laminar τ(r) acting on a CTC can also cause the cell to
enter G2/M arrest, thus inhibiting cell metastasis, while disturbed
shear patterns are hypothesized to have the opposite effect.177
Additionally, the shear rate has been hypothesized to have a more
significant effect on cell adhesion than τw. Slattery et al.
178 found
that changes in the shear rate, even more than τw, can cause a cell
to become more partial to expressing binding molecules, causing it
to adhere to the vessel wall.
Finally, differences in the metastatic capabilities between
CTCs themselves can influence their adherence to a vessel wall.179
It is known that highly metastatic CTCs form stronger bonds to the
endothelial cell layer than their more benign counterparts;165 they
also have a much higher adhesion rate than less aggressive
CTCs.180
IV. THE ENVIRONMENT OF CELL SUSPENSIONS: IN
VIVO
Suspended cells in the circulation can be exposed to a wide
range of fluidic environments: from the interstitial environment
where fluid surrounding cells is not constrained and flows at very
low velocities, to the largest arteries which resemble very high-
velocity, pulsatile pipe flows. The primary sites of microfluidic flow
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in the body occur in the lymphatic and cardiovascular capillaries.
A comparison of the LS and CS is summarized in Table VI.
A. The cardiovascular system
The cycle of the CS, the more well known and extensively
researched system, begins in the heart, when oxygenated blood is
pumped from the heart, via the aorta, to the rest of the body. From
here, arteries carry oxygenated blood to smaller arterioles and
finally, blood capillaries. The capillaries lie among the cells of the
tissue and secrete and absorb the interstitial fluid surrounding the
cells. It is here that nutrient and waste exchange takes place and
excess interstitial fluid is later absorbed by the lymphatic capillaries
(see Sec. IV B).181 Blood capillaries are also extremely small at
around 5–10 μm. Fluid flows through these capillaries by means of
a pressure difference (high pressure in arteries to low pressure in
veins) and fluid exchange in and out of the capillaries is governed
by the revised Starling principle,182
Jv
A
¼ Lm((Pc  Pi) σs(Πp Πi)), (27)
where Jv is the volume filtration rate per unit endothelial area A,
Lm is the hydraulic conductivity of the membrane, Pc is the capil-
lary hydrostatic pressure, Pi, the interstitial hydrostatic pressure, σs
is Staverman’s reflection coefficient, Πp is the osmotic pressure in
plasma, and Πi, the osmotic pressure in the interstitial fluid.
183
Blood leaving the blood capillaries travels through venules, veins,
and, finally, back to the heart.
Because of the high pressure exerted by the heart, fluid veloc-
ities in the CS can reach up to 300 mm/s. Blood is a
non-Newtonian, shear thinning fluid with a density slightly higher
than water of approximately 1060 kg/m3; however, at the scale of
capillaries, it is treated discretely. Due to the different flow regimes
in arteries, veins, or capillaries, the Re in the CS varies greatly
(approximately 1–4000), and so fluctuates between laminar and
turbulent flow. These result in a τw in the CS of 1.5–60 Pa,
6 result-
ing in ∇τp of approximately 0.004–0.023 Pa/μm.
B. The lymphatic system
The LS, like the CS, is a circulatory system; however, unlike
the CS, the LS is an open system, and lymph does not remain
exclusively within the vessels.
The lymph’s journey begins in the lymphatic capillaries, or
the initial lymphatics. These channels are found lying among the
cells and blood capillaries and contain tiny valves which open by
means of a pressure difference, absorbing the interstitial fluid.
From here, the interstitial fluid becomes known as lymph.184 The
lymphatic capillaries, like blood capillaries, are only one cell thick;
however, unlike blood capillaries, their shape tends to be inconsis-
tent with a diameter ranging from 10 to 60 μm.185,186 Following its
passage through the capillaries, lymph flows into the collecting
lymphatics, whose walls are much thicker, more muscular, and
have a larger diameter (approximately 100–300 μm).184,187–191
Instead of a pressure difference, at this stage, the LS employs a
number of different techniques in order to transport the lymph.
Muscular walls of the lymphatics can contract, squeezing the
lymph slowly along.184,192 These muscles act independently of each
other, their responses depend upon the local fluid dynamics they
are normally exposed to.193 Therefore, different vessels, depending
on their positions in the body, respond differently to changing
levels of intra-luminal pressure.194 Muscular contraction of larger
muscles, such as biceps and triceps, also squeezes the lymphatics,
causing the lymph to be pushed forward.184,192 Finally, the lym-
phatics contain valves, similar to veins. These prevent the back-flow
of lymph and ensure it remains moving forward.195–197 The valves
are biased to stay open in order to allow efficient pumping;197,198
however, should the situation require, they will close. The vessel
between two valves is known as a lymphangion.199 From the col-
lecting lymphatics, the lymph is taken via the lymphatic ducts and
returned to the blood at the subclavian veins in the shoulders.
Because of the passive nature of the LS, fluid velocities are
much lower in comparison to the CS (0.35–1 mm/s).188–191
Additionally, lymph is considered to be a Newtonian fluid with a
dynamic viscosity and density similar to those of water (approxi-
mately 1 mPa s and 1000 kg/m3 respectively).189,200,201 Each of
these individual factors combines to give lymphatic fluid flow a
very low Re, typically, Re , 1.187 Larger capillaries and lower veloc-
ities also result in a lower τw in the LS of approximately
0.065 Pa,187,189,190 and previous studies have shown that Poiseuille
flow is a valid assumption for estimation of τw in lymphatic
flow.189 Interestingly, previous computational studies have also
found that ∇τp in the LS are quite large in comparison to the CS,
reaching values of 0.004–0.137 Pa/μm.202
V. THE ENVIRONMENT OF CELL SUSPENSIONS: IN
VITRO
In vitro environments, while not the native conditions of cir-
culating cells, are more straightforward in terms of fluid mechanics.
These applications tend to revert to Newtonian fluids and undergo
laminar flow in straight, regular microchannels. Cells are exposed
to in vitro flow conditions for research, diagnostic and treatment
purposes. These applications are expanded further below.
A. Lab-on-a-chip devices
Lab-on-a-chip devices or organ-on-chip-devices primarily
replicate in vivo tissue conditions allowing for the study of specific
organs in healthy or diseased states in a controlled, biologically
accurate environment, which can also be used for researching
TABLE VI. Comparison of the cardiovascular and lymphatic systems.
Characteristic Cardiovascular system Lymphatic system
Capillary size 5–10 μm 100–300 μm
Fluid μ Shear thinning fluid Newtonian, 1 mPa s
Fluid ρ 1060 kg/m3 1000 kg/m3
Fluid Velocity ≤300 mm/s 0.35–1 mm/s
Re 1–4000 <1
τw 1.5–60 Pa 0.065 Pa
∇τp 0.004–0.023 Pa/μm 0.004–0.137 Pa/μm
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therapeutic applications.203 Many imitate cancer tissue and can be
used to replicate and study cancer metastasis,204–206 examining
cells’ migration through the extracellular matrix (ECM). Others can
be fabricated in order to resemble vascular microvessels.207–210
These vessels, however, are primarily used to either examine the
response of adherent endothelial cells to fluidic forces211–213 and
nanoparticle interactions,214 or the process of cancer migration and
intravasation215–219 in blood vessels. Some examine the same phe-
nomena in lymphatic vessels.220,221 However, the activities of sus-
pended cells already flowing within the channel are, by
comparison, less well understood. One of the few to study this,
Follain et al.,173 found that lower flow velocities were favored by
CTCs for cell arrest. As different devices are developed to investi-
gate different biological phenomena, the magnitude and type of
fluidic forces that cells experience are unique to each assay. For this
reason, cell reactions to fluidic conditions may be particularly diffi-
cult to establish for lab-on-a-chip devices without preliminary tests.
Cell viability is important in these devices as, in the case of thera-
peutic applications, it is imperative that cell damage or death can
be attributed to the variable under consideration and is unrelated
to the fluidic forces that the cells may experience in the microflui-
dic device.
B. Cell separation
The majority of applications in the inertial migration of
deformable particles lie in particle or cell sorting. Numerous
devices have been developed in order to separate different particles
from each other based on size, deformability, or surface markers.
The majority of these applications lie in the biomedical industry,
with the separation of different cell types from blood in particular.
Cell separation is often necessary for diagnostic purposes when one
cell type alone is required or, like the case of CTCs, cell enrichment
is requisite for rare cells.
1. Inertial cell separation
Inertial cell separation techniques utilize micrometer-sized
channels in order to manipulate the inertial forces acting on cells,
allowing them to be separated based on different physical parame-
ters.222 Studies that have developed this technique have been sum-
marized in Table VII along with particle separation techniques.
Cell separation differs from other in vitro cell suspension applica-
tions in that, often, cells are exposed to larger viscous drag forces
or Dean forces (see Sec. II B 2 5) within the channel,97 increasing
the risk of cell damage. Previous studies have found that WBC sol-
utions in a spiral microchannel, similar to those used in cell sorting
applications, can induce cell losses of up to 10.3% and cell defor-
mation of up to 29.8%.24 Again, cell viability and functionality is
essential for cell separation applications, as the properties of cells
will change upon cellular damage or death, resulting in potential
faulty separation.
2. Magnetic cell separation
Magnetic cell separation techniques exploit the surface pro-
teins of a specific cell type, utilizing antibodies, affixed to the
surface of magnetic beads, which then attach to the desired cell,
causing them to attach to magnetic surfaces, such as the beads of a
separation column or the walls of a surrounding magnet. This tech-
nique is commonly used for the separation of blood for research
purposes. While the use of microchannels is not as common in this
application, suspended cells are still exposed to complex forces,
increasing the risk of cell damage. Cell viability and functionality
are essential, as the properties of cells will change upon cellular
damage or death, resulting in potentially inaccurate separation.
C. Flow cytometry
Flow cytometry is a microfluidic method used to measure or
identify cell characteristics by illumination of fluorescently tagged
cells as they flow past a light source.223,224 It can be used for diag-
nosis of certain conditions by the physical properties (size or
deformability), chemical properties (expression of proteins), or
simply by the presence or absence of the cells. For example,
fluorescence-activated cell sorting (FACS), counts or sorts cells by
means of the presence or absence of a fluorescent antibody, which
attaches to the surface of the cell due to the presence of a specific
surface protein.153 Again, like the majority of flow cytometry tech-
niques, a microchannel is used to expose the cell surface to a laser,
producing a signal for cell analysis. This technique can be used as a
standalone procedure or can be used in conjunction with cell sepa-
ration techniques for faster processing. Within these channels, τw
may reach values of up to 0.9–1.4 Pa. Like cell separation, it is
important that both cell viability and functionality remain unaf-
fected by the fluidic forces from the channel that the cells are trav-
eling in, to prevent false diagnosis.
D. Patient therapies
Microchannels are commonly used in clinical settings to
extract cell suspensions from patients and return them to the body.
Dialysis, used in patients with kidney failure to remove blood from
the body, extract toxins and return it to the body, has been shown
to disturb the local haemodynamics, leading to hyperplasia, steno-
sis, and ultimately, thrombosis of the endothelial cell lining.232 It is
reasonable to assume that a similar damage may occur to sus-
pended cells due to disrupted flow patterns. Similarly, apheresis,
used in both donation (for example, blood plasma and platelets)
and therapeutic purposes (for example, in leukemia or haemochro-
matosis) for isolation and removal of specific cell types from the
blood, can induce disturbed local haemodynamics. Not only is
there a change in the local fluid dynamics at the access points, but
in both cases, cells are passed through microchannels at high veloc-
ities and, in the case of apheresis, may also undergo centrifugation,
resulting in a variety of forces acting on the cell with a potential for
cell damage. In these applications, the retention of cell viability and
competence is paramount, as cells are returned to the body of the
patient.
E. Adoptive cell transfer
One of the most exciting and novel emerging areas of cancer
research, adoptive cell transfer (ACT), promises to change the way
cancer and autoimmune diseases are conventionally treated.
Autologous cancer immunotherapy involves the removal of T-cells
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TABLE VII. Summary of the developed particle inertial separation techniques.
Separated particle(s) (dp)
Separated
from Channel description Re/Q Study
Spherical particles (15.5 μm), spherical
particles (18.7 μm), spherical particles
(26.3 μm), spherical particles (31.2 μm),
white blood cells (≥7 μm)
PBS, whole
blood
45 × 120 μm2 rectangular cross section
sheath flow (particles), 50 × 150 μm2
rectangular cross section sheath flow—
20 mm long (cells)
QBlood =QPBS = 112.5
μl/min (particles), QBlood
= 133 μl/min QPBS = 267
μl/min (cells)
225
PDMS particles (20 μm), lung cancer cells
(NSCLC) (11–27 μm), prostate cancer cells




Vortex chip: 70 × 40 μm2 rectangular
cross section broadening to ×8 reservoirs
in series with ×8 channels in parallel
Re = 150–160 83
Particles (6 μm), particles (15 μm), breast
cancer cells (MCF-7) (15–20 μm), breast
cancer cells (MDA-MB-231) (15–20 μm),
cervical cancer cells (HeLa) (15–20 μm)
PBS, whole
blood
160 × 500 μm2 rectangular cross section
—10 cm long in a two-loop spiral
Re≈ 50 63
Polystyrene particles (1 μm), polystyrene
particles (4.8 μm)
Water 75 μm ID circular cross section—5–60
cm long
Re = 5.6–28 226
Polystyrene particles (7.32 μm),
polystyrene particles (10 μm), polystyrene




75 × 250 μm2 rectangular cross section—
6 cm long in a four-loop spiral, 110 ×
500 μm2 rectangular cross section—8 cm
long in a four-loop spiral
Q = 1–3 ml/min 64
Polystyrene particles (5 μm), polystyrene




85 × 300 μm2 rectangular cross section—
334 mm long in a six-loop double spiral
Re = 18–106 65
Particles (9.94 μm), particles (20 μm),
prostate cancer cells (18–22 μm)
Water,
whole blood
50 × 27 μm2 rectangular cross section—
10.3 mm long broadening to 50 × 100
μm2 rectangular cross section—9.2 mm
long
Re = 30–80 66
Polystyrene particles (3 μm), polystyrene
particles (6 μm), polystyrene rods (AR:1:3),
polystyrene rods (AR:1:5)
Water 47 × 25 μm2 rectangular cross section—
4 cm long, 47 × 30 μm2 rectangular cross
section—4 cm long, 47 × 35 μm2
rectangular cross section—4 cm long
Re = 13–72 227
Breast cancer cells (MCF-7) (18.1 μm),
breast cancer cells (MDA-MB-231) (18.2
μm)
PBS 20 μm wide rectangular cross section—
100 μm long broadening to 60 μm wide
rectangular cross section—100 μm long
with ×75 reservoirs in series
Re = 10–150 80
PDMS particles (2–30 μm), oil droplets
(6-20 μm), leukocytes, cervical cancer cells




93 × 40 μm2 rectangular cross section—
4.5 cm long broadening to five branched
outlets
Re = 21–42 23
Polystyrene particles (1 μm), polystyrene
particles (4.8 μm), polystyrene particles
(9.9 μm), cervical cancer cells (HeLa)




70 × 50 μm2 rectangular cross section
with ×10 reservoirs broadening to 70 ×
400 μm2 rectangular cross section—
400 μm2 long in series with ×8 channels
in parallel
Re = 5–270 81
Polystyrene particles (6 μm),
neuroblastoma cells (SH-SY5Y) (15 μm)
Water, PBS 50 × 100 μm2 rectangular cross section—
25 cm long in a ten-loop spiral, 120 ×
500 μm2 rectangular cross section—
40 cm long in a five-loop spiral
Re≈ 20 224
Polystyrene particles (3 μm), polystyrene
particles (6 μm), red blood cells
(approximately 6 μm), malaria-infected red
blood cells (approximately 3 μm)
Whole
blood
10 × 15 μm2 rectangular cross section—
3 cm long with three outlets
Q = 0.2–5 μl/min 13
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from the patient’s body, followed by modification and a return to
the body of the same patient, reducing the risk of a foreign body
response, while allogenic therapies involve separate donor and
patient, advantageous in cases where patient cell counts have
already been severely blighted.233 In early studies, tumor-infiltrating
lymphocytes (TILs) were extracted from patients’ excised tumors,
cultured in vitro, and returned to the patient’s body to treat mela-
noma.234 Antigen-expanded T-cell therapy operates on a similar
principle; however, extracted T-cells are reactivated to recognize
specific tumor-associated antigens, while T-cell receptor (TCR)
therapy and CAR T-cell therapy involve the genetic reprograming
of killer T-cells from the cancer patient to express T-cell receptors
and chimeric-antigen receptor, respectively, before being returned
to the patient’s body.234,235 ACT processing steps in vitro involve
blood extraction, followed by cell separation techniques, and flow
cytometry as previously described, and so, make use of microchan-
nels. As the cells are being harvested from a patient with precious
few T-cells that may already be quite weak due to patient treatment,
it is imperative that the cells are not impaired further in any way
by the T-cell extraction and treatment process. Additionally, as the
patient has an already severely compromised immune system, it is
critical to ensure certainty that returned T-cells are not impaired or
damaged in any way by the forces that they are exposed to in these
channels.
VI. CONCLUSIONS AND FUTURE PERSPECTIVES
Currently, there is an extensive understanding of the advection
of rigid particles in microchannels. A level of complexity is added,
however, when deformable particles are used, particularly when the
deformable particles are living cells, whose functionality and viabil-
ity can also be impacted by the same fluidic forces that dictate their
location in the channel.
While previous studies have attempted to assess the effect that
these forces have on the viability and functionality of the cell, it is
still difficult to ascertain the validity of these results as it is difficult
to quantify these forces or to understand, which individual forces
contribute to such effects. This is because test methods which are
currently used to apply shear stresses to cell suspensions cannot




from Channel description Re/Q Study
Polystyrene particles (7.9 μm), red blood




60 × 20 μm2 rectangular cross section—
4 mm long broadening at 0.2° to 60 ×
160 μm2 rectangular cross section with
three outlets
Re = 17–84 62




50 μm2 square cross section Re = 0–0.37 228
Polystyrene particles (10 μm), polystyrene
particles (15 μm), polystyrene particles (20
μm), neuroblastoma cells (SH-SY5Y) (15
μm), rat glioma cells (C6) (8 μm)
Water, PBS 90–140 × 500 μm2 rectangular cross
section in a six-loop spiral
229
Polystyrene particles (1.9 μm), polystyrene
particles (7.32 μm)
Water 50 × 100 μm2 rectangular cross section—
13 cm long in a five-loop spiral
Re≤ 10 47
Polystyrene particles (3.1 μm), polystyrene
particles (9 μm), oil droplets (≤20 μm),
PDMS particles (≤20 μm)
Water 50 × 350–650 μm2 rectangular cross
section, ellipse-shaped units 31 units in
length
Q = 0.9 ml/min 230
Polystyrene particles (2 μm), polystyrene
particles (3 μm), polystyrene particles (4
μm), polystyrene particles (7 μm),
polystyrene particles (9 μm), polystyrene
particles (17 μm), oil droplets (≤20 μm),
lung cancer cells (H1650)
PBS, whole
blood
Ellipse-shaped units Re = 0.075–225 38




75 μm height rectangular cross section
narrowing to 75 × 15–50 μm2 rectangular
cross section—50–300 μm long
broadening to 75 μm height rectangular
cross section
Re = 0.01 22
Polymer particles (0.71 μm), polymer
particles (1 μm), polymer particles (2.1
μm), polymer particles (3 μm), polymer
particles (5 μm), blood cells (7-8 μm)
Water,
whole blood
Multichannel Q = 20–1000 μl/h 231
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(syringe and needle) or exert additional unknown strains on the
suspended cells (continuous flow circuits). Additionally, in the
latter two methods, it is difficult to ascertain the shear stress that
cells in suspension are actually exposed to. For this reason, there is
a need to develop a test method that will not only apply a continu-
ous, non-compressive shear force to suspended cells in pipe flow
over an extended period of time but also incorporate a method that
will allow for a more accurate estimation of the shear forces
imposed on the cells than the τw value.
From the conducted review, it is clear that there are significant
gaps in the current knowledge on cells in suspension that require
further study. While a number of studies have examined the inertial
migration of particles and cells in rigid microchannels, to the
authors knowledge, none have looked at the same effects in deform-
able channels. Future studies in deformable channels will aid us in
the understanding of cell advection in the capillaries, potentially fur-
thering our knowledge of nutrient exchange or cancer metastasis,
and could be extended further to incorporate similar studies in
excised vessels. In contrast, the majority of viability studies in circula-
tory models examine this outcome only in deformable microchan-
nels and have not compared these results to the viability in
rigid-walled channels. This makes it difficult to estimate the viability
of these cells in certain in vitro channels, as the native environment
of these cells being one with deformable channel walls may result in
reduced viability outside of these situations.
Additionally, while it is evident from the published literature
that a change in deformability results in a change in inertial migra-
tion, with a possible change in cell viability rates, the extent of the
influence of the deformability change is unclear. Indeed, currently
many cell separation devices already rely on this phenomenon that
different cells occupy different inertial positions due to their size or
deformability. However, it is still unknown if these are the only
physical properties that influence a cell’s position. Further experi-
mentation and computational work will confirm this.
This leads to uncertainty in microfluidic therapeutics, diagnostics,
and research as unquantified forces, such as the shear stress on the
cell surface, or the shear rate that the cell is exposed to, may be affect-
ing the cell in an unknown capacity, potentially giving false negatives
in the case of diagnostics or, in the case of therapeutics, resulting in
the further depletion of an already compromised and weak cell source.
For this reason, it is vital that these effects are not only identified
but also quantified in order to ensure the best outcomes for patients.
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